CN101679442B - 用于治疗丙型肝炎的化合物 - Google Patents

用于治疗丙型肝炎的化合物 Download PDF

Info

Publication number
CN101679442B
CN101679442B CN2008800163092A CN200880016309A CN101679442B CN 101679442 B CN101679442 B CN 101679442B CN 2008800163092 A CN2008800163092 A CN 2008800163092A CN 200880016309 A CN200880016309 A CN 200880016309A CN 101679442 B CN101679442 B CN 101679442B
Authority
CN
China
Prior art keywords
cyclohexyl
mmol
methoxy
indolo
benzazepine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN2008800163092A
Other languages
English (en)
Chinese (zh)
Other versions
CN101679442A (zh
Inventor
约翰·A·本德
罗伯特·G·金特尔斯
韩迎
涂勇
杨忠
杨革新
凯瑟琳·A·格兰特-扬
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bristol Myers Squibb Co
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of CN101679442A publication Critical patent/CN101679442A/zh
Application granted granted Critical
Publication of CN101679442B publication Critical patent/CN101679442B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
CN2008800163092A 2007-03-14 2008-03-13 用于治疗丙型肝炎的化合物 Expired - Fee Related CN101679442B (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US89488407P 2007-03-14 2007-03-14
US60/894,884 2007-03-14
US98947007P 2007-11-21 2007-11-21
US60/989,470 2007-11-21
PCT/US2008/056766 WO2008112841A1 (en) 2007-03-14 2008-03-13 Compounds for the treatment of hepatitis c

Publications (2)

Publication Number Publication Date
CN101679442A CN101679442A (zh) 2010-03-24
CN101679442B true CN101679442B (zh) 2013-02-20

Family

ID=39473826

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2008800163092A Expired - Fee Related CN101679442B (zh) 2007-03-14 2008-03-13 用于治疗丙型肝炎的化合物

Country Status (6)

Country Link
US (1) US7521444B2 (enExample)
EP (1) EP2121697B1 (enExample)
JP (1) JP5209647B2 (enExample)
CN (1) CN101679442B (enExample)
AT (1) ATE522532T1 (enExample)
WO (1) WO2008112841A1 (enExample)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1688420A4 (en) * 2003-11-19 2008-10-22 Japan Tobacco Inc 5-5 LOW-CONDENSED HETEROCYCLIC COMPOUND AND THEIR USE AS HCV POLYMERASE INHIBITOR
US20070049593A1 (en) * 2004-02-24 2007-03-01 Japan Tobacco Inc. Tetracyclic fused heterocyclic compound and use thereof as HCV polymerase inhibitor
US7659263B2 (en) 2004-11-12 2010-02-09 Japan Tobacco Inc. Thienopyrrole compound and use thereof as HCV polymerase inhibitor
US7521443B2 (en) * 2006-05-17 2009-04-21 Bristol-Myers Squibb Company Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors
US7642251B2 (en) * 2007-08-09 2010-01-05 Bristol-Myers Squibb Company Compounds for the treatment of hepatitis C
US8143243B2 (en) * 2007-08-09 2012-03-27 Bristol-Myers Squibb Company Compounds for the treatment of hepatitis C
US7652004B2 (en) * 2007-08-09 2010-01-26 Bristol-Myers Squibb Company Compounds for the treatment of hepatitis C
PL2209789T3 (pl) * 2007-11-20 2012-04-30 Bristol Myers Squibb Co Skondensowane z cyklopropylem indolobenzoazepinowe inhibitory NS5B HCV
US8129367B2 (en) * 2007-11-21 2012-03-06 Bristol-Myers Squibb Company Compounds for the treatment of Hepatitis C
US8124601B2 (en) * 2007-11-21 2012-02-28 Bristol-Myers Squibb Company Compounds for the treatment of Hepatitis C
EP2280978B1 (en) * 2008-03-27 2013-04-24 Bristol-Myers Squibb Company Pyrrolidine fused indolobenzadiazepine hcv ns5b inhibitors
US8138171B2 (en) * 2008-03-27 2012-03-20 Bristol-Myers Squibb Company Dioxolane and dioxolanone fused indolobenzadiazepine HCV NS5B inhibitors
US8178523B2 (en) * 2008-03-27 2012-05-15 Bristol-Myers Squibb Company Compounds for the treatment of hepatitis C
US8133884B2 (en) * 2008-05-06 2012-03-13 Bristol-Myers Squibb Company Compounds for the treatment of hepatitis C
US8143244B2 (en) * 2009-02-26 2012-03-27 Bristol-Myers Squibb Company Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors
WO2013030750A1 (en) 2011-09-01 2013-03-07 Lupin Limited Antiviral compounds
AU2013217224B2 (en) 2012-02-10 2017-04-06 Lupin Limited Antiviral compounds with a dibenzooxaheterocycle moiety
US12274700B1 (en) 2020-10-30 2025-04-15 Accencio LLC Methods of treating symptoms of coronavirus infection with RNA polymerase inhibitors

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006020082A1 (en) * 2004-08-09 2006-02-23 Bristol-Myers Squibb Company Inhibitors of hcv replication
WO2006046030A2 (en) * 2004-10-26 2006-05-04 Istituto Di Ricerche Di Biologia Molecolare P Angeletti Spa Tetracyclic indole derivatives as antiviral agents
WO2007136982A1 (en) * 2006-05-17 2007-11-29 Bristol-Myers Squibb Company Cyclopropyl fused indolobenzazepine hcv ns5b inhibitors
WO2007140109A1 (en) * 2006-05-22 2007-12-06 Bristol-Myers Squibb Company Cyclopropyl fused indolobenzazepine hcv ns5b inhibitors
WO2007143521A1 (en) * 2006-06-08 2007-12-13 Bristol-Myers Squibb Company Cyclopropyl fused indolobenzazepine hcv inhibitors

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE602005013922D1 (de) 2004-02-24 2009-05-28 Japan Tobacco Inc Kondensierte heterotetracyclische verbindungen und deren verwendung als hcv-polymerase-inhibitor
US7348425B2 (en) 2004-08-09 2008-03-25 Bristol-Myers Squibb Company Inhibitors of HCV replication
GB0518390D0 (en) 2005-09-09 2005-10-19 Angeletti P Ist Richerche Bio Therapeutic compounds
US7399758B2 (en) * 2005-09-12 2008-07-15 Meanwell Nicholas A Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors
US7473688B2 (en) 2005-09-13 2009-01-06 Bristol-Myers Squibb Company Indolobenzazepine HCV NS5B inhibitors
US7456165B2 (en) 2006-02-08 2008-11-25 Bristol-Myers Squibb Company HCV NS5B inhibitors
GB0608928D0 (en) 2006-05-08 2006-06-14 Angeletti P Ist Richerche Bio Therapeutic agents
US7521442B2 (en) 2006-05-25 2009-04-21 Bristol-Myers Squibb Company Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors
CN101490054B (zh) 2006-05-25 2012-05-16 百时美施贵宝公司 环丙基稠合的吲哚并苯并氮杂*hcv ns5b抑制剂

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006020082A1 (en) * 2004-08-09 2006-02-23 Bristol-Myers Squibb Company Inhibitors of hcv replication
WO2006046030A2 (en) * 2004-10-26 2006-05-04 Istituto Di Ricerche Di Biologia Molecolare P Angeletti Spa Tetracyclic indole derivatives as antiviral agents
WO2007136982A1 (en) * 2006-05-17 2007-11-29 Bristol-Myers Squibb Company Cyclopropyl fused indolobenzazepine hcv ns5b inhibitors
WO2007140109A1 (en) * 2006-05-22 2007-12-06 Bristol-Myers Squibb Company Cyclopropyl fused indolobenzazepine hcv ns5b inhibitors
WO2007143521A1 (en) * 2006-06-08 2007-12-13 Bristol-Myers Squibb Company Cyclopropyl fused indolobenzazepine hcv inhibitors

Also Published As

Publication number Publication date
CN101679442A (zh) 2010-03-24
JP2010521481A (ja) 2010-06-24
EP2121697A1 (en) 2009-11-25
US7521444B2 (en) 2009-04-21
JP5209647B2 (ja) 2013-06-12
ATE522532T1 (de) 2011-09-15
WO2008112841A1 (en) 2008-09-18
US20080226590A1 (en) 2008-09-18
EP2121697B1 (en) 2011-08-31

Similar Documents

Publication Publication Date Title
CN101679442B (zh) 用于治疗丙型肝炎的化合物
CN101918410B (zh) 与环丙基稠合的吲哚并苯并氮杂*hcv ns5b抑制剂
CN101730698B (zh) 用于治疗丙型肝炎的化合物
CN101679441B (zh) 用于治疗丙型肝炎的化合物
CN101631790B (zh) 用于治疗丙型肝炎的化合物
US7485633B2 (en) Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors
EP2118109B1 (en) Compounds for the treatment of hepatitis c
EP2024375B1 (en) Cyclopropyl fused indolobenzazepine hcv ns5b inhibitors
CN101918412B (zh) 用于治疗丙型肝炎的稠合有环丙基的吲哚并苯并氮杂*衍生物
EP2209784B1 (en) Compounds for the treatment of hepatitis c
EP2118110B1 (en) Cyclopropyl fused indolobenzazepine hcv inhibitors
EP2401280B1 (en) Cyclopropyl fused indolobenzazepine hcv ns5b inhibitors
CN101646674B (zh) 用于治疗丙型肝炎的吲哚并苯并氮杂*衍生物
EP2121694B1 (en) Cyclopropyl fused indolobenzazepine hcv ns5b inhibitors
CN101443336B (zh) 环丙基稠合的[吲哚]并[苯并氮杂*]hcv ns5b抑制剂
ES2370121T3 (es) Compuestos para el tratamiento de la hepatitis c.
HK1122814B (en) Cyclopropyl fused indolobenzazepine hcv ns5b inhibitors

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C53 Correction of patent of invention or patent application
CB03 Change of inventor or designer information

Inventor after: Bender John A.

Inventor after: Gentles Robert G.

Inventor after: Han Ying

Inventor after: Tu Yong

Inventor after: Yang Zhong

Inventor after: Yang Gexin

Inventor after: Grant-young Katharine A.

Inventor before: Bender John A.

Inventor before: Gentles Robert G.

Inventor before: Yin Han

Inventor before: Tu Yong

Inventor before: Yang Zhong

Inventor before: Yang Gexin

Inventor before: Grant-young Katharine A.

COR Change of bibliographic data

Free format text: CORRECT: INVENTOR; FROM: JOHN A BEND ROBERT G GENTLES YIN HAN TU YONG YANG ZHONG YANG GEXIN CATHERINE A GRANT-YANG TO: JOHN A BEND ROBERT G GENTLES HAN YING TU YONG YANG ZHONG YANG GEXIN CATHERINE A GRANT-YANG

C14 Grant of patent or utility model
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20130220

Termination date: 20150313

EXPY Termination of patent right or utility model